Expand Program on Immunization, Chongqing Center for Disease Control and Prevention, Chongqing, China.
Expand Program on Immunization, Yuzhong District Center for Disease Control and Prevention, Chongqing, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2389602. doi: 10.1080/21645515.2024.2389602. Epub 2024 Aug 22.
The factors affecting the antibody responses to the ZF2001 vaccine remain unknown. To address this, we conducted a cross-sectional serological study in the real world. Adults with no prior SARS-CoV-2 infection history and received three doses of ZF2001 vaccine were invited to our study in the early stages of the COVID-19 epidemic in Chongqing between 7 April 2021 and 17 November 2021. A questionnaire survey was conducted to obtain demographic characteristics, health information, and the frequency of lifestyles at the time of enrollment. A total of 266 eligible subjects aged 18 to 86 years, with a median age of 56.00 (IQR: 34-66) participated. 68.80% of them were female. Hypertension (13.16%) and diabetes (6.02%) were common comorbidities. Serum samples were collected at one month after the third dose of ZF2001 vaccination, and serological testing was conducted using the Pseudovirus-Based Neutralization Assay. The chi-square test was employed to compare seropositivity rates, and the Mann-Whitney U test or the Kruskal-Wallis test was used to analyze the neutralizing antibodies level in stratified groups. Subsequently, univariate and multivariate linear regression analyses were conducted to identify the influencing factors. We observed that seropositivity rates was 76.32%, with 95% confidence interval (95%CI) 70.85%-81.03%, and geometric mean titer (GMT) was 120.26, with 95%CI 100.38-144.08. Age, diabetes, and frequently of alcohol were negative associations with antibody response ( = -0.2021, 95% CI: -0.2507 to -0.1535, = -0.2873, 95% CI: -0.5590 to -0.0155, = -0.2082, 95% CI: -0.3419 to-0.0746, < 0.0001, = 0.0384, = 0.0024). Conversely, the -interval between 1 and 2 dose and frequently of tea were positive associations with antibody response ( = 0.1369, 95% CI: 0.0463 to 0.2275, = 0.0830, 95% CI: 0.0106 to 0.1554, = 0.0032, = 0.0247). Overall, the ZF2001 vaccine-induced antibody response was influenced by a multifactor that may provide a reference for the development of personalized antigen vaccines and vaccination strategies in the future.
影响 ZF2001 疫苗抗体反应的因素尚不清楚。为了解决这个问题，我们在 COVID-19 疫情早期在重庆进行了一项真实世界的横断面血清学研究。2021 年 4 月 7 日至 11 月 17 日期间，邀请无 SARS-CoV-2 感染史且接种了三剂 ZF2001 疫苗的成年人参加我们的研究。我们通过问卷调查获得了人口统计学特征、健康信息和接种时的生活方式频率。共纳入了 266 名年龄在 18 至 86 岁之间、中位年龄为 56.00（IQR：34-66）的合格受试者，其中 68.80%为女性。常见合并症有高血压（13.16%）和糖尿病（6.02%）。在接种 ZF2001 疫苗第三剂后一个月采集血清样本，并使用假病毒中和测定法进行血清学检测。采用卡方检验比较血清阳性率，采用 Mann-Whitney U 检验或 Kruskal-Wallis 检验对分层组的中和抗体水平进行分析。随后，进行单变量和多变量线性回归分析以确定影响因素。我们观察到血清阳性率为 76.32%，95%置信区间（95%CI）为 70.85%-81.03%，几何平均滴度（GMT）为 120.26，95%CI 为 100.38-144.08。年龄、糖尿病和饮酒频率与抗体反应呈负相关（= -0.2021，95%CI：-0.2507 至-0.1535，= -0.2873，95%CI：-0.5590 至-0.0155，= -0.2082，95%CI：-0.3419 至-0.0746，<0.0001， = 0.0384， = 0.0024）。相反，1 剂至 2 剂的间隔时间和饮茶频率与抗体反应呈正相关（ = 0.1369，95%CI：0.0463 至 0.2275， = 0.0830，95%CI：0.0106 至 0.1554， = 0.0032， = 0.0247）。总体而言，ZF2001 疫苗诱导的抗体反应受多种因素影响，可为未来个性化抗原疫苗和接种策略的制定提供参考。
